Clinical research is going through a period of rapid digitization, across all phases of drug development. With the increasing focus on Phase IV and real-world evidence (RWE) comes the need to capture more data, at a higher level of quality, directly from patients. The problem is, how to engage patients effectively and at scale, all while managing spiralling costs and ensuring validation and control?
The rise of the ubiquitous smartphone has unlocked a new approach – BYOD, allowing patients to use their own devices for clinical research. By engaging the patient to use their own device, virtual and siteless trials become a reality.
In this webinar, featured industry speakers will share their unfiltered insights on how to take advantage of these trends, and share case studies, including the 16,500 participant, direct-to-patient, ‘Cloudy with a Chance of Pain’ study(1) and the largest sleep and rheumatoid arthritis study ever performed. You will hear about the benefits of a patient-centric approach for all stakeholders, leading to greater patient engagement, more data capture and faster studies.
Professor Will Dixon, Chair in Digital Epidemiology, University of Manchester
Will Dixon qualified from Guy’s and St. Thomas’ Hospitals, London, trained as a rheumatologist in Manchester, UK and has higher degrees from The University of Manchester and McGill University, Montreal. He is a Professor of Digital Epidemiology, Director of the Arthritis Research UK Centre for Epidemiology at the University of Manchester and an honorary consultant rheumatologist at Salford Royal NHS Foundation Trust.Message Presenter
Willie Muehlhausen, eCOA Subject Matter Expert, Muehlhausen Ltd
Willie Muehlhausen has been involved in the collection and migration of PROs since 1998. During his career, he worked with multiple technologies to capture PRO data, and in 2009, he started his research program to understand BYOD and its implications. In collaboration with multiple organizations (sponsors and vendors) his team conducted and published several unique studies (i.e. first BYOD equivalence study) all trying to establish a basic understanding of how different technologies influence patients’ responses. Willie is now supporting uMotif as their special advisor for eCOA.Message Presenter
Bruce Hellman, CEO and Co-Founder, uMotif
Bruce is the CEO of uMotif and co-founded the company in 2012. He and his team have developed the leading platform for real-world and observational research – a modern data capture platform that patients love to use. Bruce began his career working in clinical trials at British Biotech before joining the UK Civil Service Fast Stream in the Department for Culture, Media and Sport. Prior to founding uMotif, Bruce worked at Serco and completed an Executive MBA from Imperial College Business School.Message Presenter
Who Should Attend?
- ePRO/eCOA Category Managers
- Data Managers
- RWE and Late Phase Clinical Trial/Clinical Study Leads
- Therapeutic Strategy Leads
- HEOR Directors
What You Will Learn
Join this webinar to learn:
- About the benefits of a patient-centric approach to clinical research
- How to take advantage of new trends in BYOD technology for ePROs
- Case studies, including the Cloudy with a Chance of Pain study
uMotif is the modern data capture platform that patients love to use. uMotif’s patient-centred approach has made them a leader in late phase and RWE research and has captured over 65 million data points from more than 20,000 patients across 21 clinical conditions. The scalable, cloud-based platform is an Amazon Web Services case study and is being used by 8 of the top 20 pharmaceutical companies in the world including AstraZeneca, Novartis and Merck. Visit www.umotif.com